First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

Related Keywords

Germany ,United States ,Joerg Scheier ,Efthymios Deliargyris ,Stefan Kluge ,Eric Kim ,Twitter ,Us Department Of Health ,Human Services ,Material Command ,National Institutes Of Health ,Us Air ,Corporate Communications ,European Union ,Affairs Critical Care Of Cytosorbents ,Facebook ,Us Army ,Blood Institute ,Cytosorbents Corporation ,National Heart ,Professor Stefan Kluge ,Vice President ,Medical Affairs Critical Care ,Chief Medical Officer ,Treatment Of Critically Ill Patients ,Sorbents Corporation ,Use Authorization ,Removal System ,Timely Antithrombotic Removal Ticagrelor ,National Institutes ,Operations Command ,Air Force Material Command ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Relations Contact ,Anne Powers ,Investor Relations ,